Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide

Simple item page
dc.contributor.authorErten, C
dc.contributor.authorKaraca, B
dc.contributor.authorKucukzeybek, Y
dc.contributor.authorGorumlu, G
dc.contributor.authorCengiz, E
dc.contributor.authorGul, MK
dc.contributor.authorAtmaca, H
dc.contributor.authorUzunoglu, S
dc.contributor.authorKarabulut, B
dc.contributor.authorSanli, UA
dc.contributor.authorUslu, R
dc.date.accessioned2024-07-18T12:01:09Z
dc.date.available2024-07-18T12:01:09Z
dc.description.abstractOBJECTIVE To evaluate the effects of combined treatment with docetaxel and octreotide, a somatostatin analogue, on human hormone- and drug-refractory prostate cancer cell lines, PC-3 and DU-145, and on some growth factors related to tumour growth and angiogenesis in prostate cancer. MATERIALS AND METHODS A cell proliferation assay was used to assess the cytotoxicity of the drugs. To verify apoptosis, both DNA fragmentation (by enzyme-linked immunosorbent assay) and caspase 3/7 activity were measured. We also investigated the effect of combined docetaxel and octreotide on growth factors secreted from prostate cancer cells using a human growth factor antibody array. RESULTS The combination of docetaxel and octreotide resulted in significant synergistic cytotoxic activity and apoptosis, which was dose- and time-dependent. The combined treatment also resulted in significantly less secretion of stem cell factor and platelet-derived growth factor-AB in PC-3 cells, and transforming growth factor-beta and basic fibroblast growth factor in DU-145 cells, than in untreated controls. CONCLUSION Octreotide, a somatostatin analogue, combined with docetaxel might provide a rationale treatment option for hormone-refractory prostate cancer cells, not only by direct inhibition of cell proliferation but also by inhibiting the secretion of growth factors.
dc.identifier.issn1464-4096
dc.identifier.other1464-410X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/8233
dc.language.isoEnglish
dc.publisherWILEY
dc.subjectSOMATOSTATIN ANALOG
dc.subjectLNCAP
dc.subjectBETA
dc.subjectEXPRESSION
dc.subjectRECEPTOR
dc.subjectLINE
dc.titleRegulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu